About Mitochondrial Medicine 2022

On June 8-11, 2022, the United Mitochondrial Disease Foundation (UMDF) hosted Mitochondrial Medicine 2022 (MitoMed22) - This was a four-day scientific meeting conference directed toward the scientist and clinician interested in all aspects of mitochondrial science. The content of this educational program was determined by rigorous assessment of educational needs and includes surveys, program feedback, expert faculty assessment, literature review, medical practice, chart review and new medical knowledge.  

Select courses from MitoMed2022 are now included on Mito U as enduring material. The UMDF proudly hosts annual symposia, bringing together the mitochondrial medicine community. For more information about UMDF, visit www.umdf.org/symposium .

Note: If you attended the live symposium in June of 2022 and claimed credit for the live courses, you are NOT eligible to submit for the enduring material.
Continuing Medical Education Course Information

 

COURSE DESCRIPTION

The United Mitochondrial Disease Foundation and PeerPoint Medical Education Institute have joined efforts to sponsor and organize a CME-accredited activity. Mitochondrial diseases are more common than previously recognized and mitochondrial pathophysiology is now a recognized part of many disease processes, including heart disease, cancer, AIDS, diabetes and autism. The enduring material was derived from the June 2022 live meeting which was directed toward the scientist and clinician interested in obtaining a comprehensive update on mitochondrial medicine. The format included didactic lectures from invited experts intermixed with a rigorous virtual panel discussion. 

 

TARGET AUDIENCE

Neurologists, Geneticists, Researchers/Scientists, Pediatrics, Internal Medicine, Nephrologists, Cardiologists, Endocrinologists, Genetic Counselors, Advanced Practice Nurses, Physicians Assistants, RNs, Occupational Therapy, Physical Therapy and Speech-Language Pathology, Nutritional Therapy, and Residents/Fellows/Students.

 

ACCREDITATION AND DESIGNATION STATEMENTS

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and the United Mitochondrial Disease Foundation. PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.

PeerPoint Medical Education Institute designates the enduring formats for this educational activity for a maximum of 6.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Live activity dates: June 8 – June 11, 2022

Enduring activity dates: September 1, 2022 – August 31, 2024

 

LEARNING OBJECTIVES

  • Learn about new clinical trials investigating small molecule therapies for primary mitochondrial diseases in children and adults
  • Understand the development of gene therapies and oligonucleotide therapies in other disease models and how they could be used to treat mitochondrial diseases in children and adults
  • Develop an understanding of mitochondrial quality control and how this concept can help better understand mitochondrial function in the disease state
  • Understand the role of cellular stress and mitochondrial function
  • Identify and manage acute multi-organ involvement
  • Learn about current and future therapies for LHON
  • Learn about the challenges and limitations of care for adults with mitochondrial and metabolic diseases
  • Review the common movement disorders present in Leigh Syndrome Patients
  • Learn about the factors encountered during spaceflight that cause mitochondrial dysfunction.
  • Understand that mitochondrial dysfunction places biological limits on long-term space flight and contributes to an accelerated pace of aging in adults that is about 10-times faster than on Earth.
  • Understand that each of the measured cellular and physiologic symptoms of long-term spaceflight is traceable to the fundamental change in mitochondrial function and bears similarities to the symptoms of genetic forms of primary mitochondrial disease in adults.
  • Learn about some of the mitochondrial changes produced by exposure to early environmental stress that increase the risk of autism.
  • Understand the role of maternal autoimmunity and the antibody targets that increase the risk of autism.
  • Learn about some forms of early intervention that have be shown to improve outcomes in some persons with autism.
  • Learn about how changes in the microbiome and microbe-associated metabolism can change child behavior and immune system development.